Member Info for Gunner68

Time for Parker to go

EGM should be called and resignations tendered

Time to get rid of BOD years in the waiting what exactly do they do a total F@@k up

Just seen HL 145 to sell ?

I’m under the firm belief nothing is happening apart from a simple delay with CTA have just phoned the number which I put up a few days ago and Lazarus also posted about delays in the process and it was confirmed by someone who works there would love to see a deal come after /if we get the CTA but till then just all speculation
GLA
Tyk toc

I understand that but if that was the case should this not be released in an RNS

SOG again if it’s a basic requirement to prove funding for phase 1a,b this should of been sorted before applying and it shows that no matter how good the science could be but how amateur the rest of the BOD are

https://r.search.yahoo.com/_ylt=Awr.oCIj82NjkbwPO510g81Q;_ylu=Y29sbwNpcjIEcG9zAzQEdnRpZAMEc2VjA3Ny/RV=2/RE=1667523491/RO=10/RU=https%3a%2f%2fwww.gov.uk%2fguidance%2fclinical-trials-for-medicines-apply-for-authorisation-in-the-uk/RK=2/RS=XcAAGxLdGF9a0eEAytB2Qe9lgzg-
A complete guide to CTA also just phoned the Manchester unit to see how long it would take to start a trial once a company has been in touch and ready to go the answer was basically weeks on average a month and with the Xmas break comming up in less than 7 weeks about time SAR got their skates on or are they still HOPE ing they will still start this year
GLA

I carnt see why we applied for a CTA without the necessary funding in place a deal could take months which means no trial taking place this year hence the word hope in the RNS is this being deliberately done to drag the sp even lower

From the latest RNS
The Phase 1a part of the trial is expected to provide safety and dosing information applicable for any future trials in patients with other autoimmune diseases and the acute respiratory symptoms of viral infections, including COVID-19, should the Company decide to progress such trials.
Once ph1a has been completed and the data is good then I believe they will apply for funding for Agile which will add value to the sp

SCHeckler when I phoned today the bloke said calendar days

Just now ?

Potnak they ve said in the past they had a deal sorted and nothing if they knew they had to have all this then why hadn’t they prepared it all in advance even in the RNS they said they were waiting for approval which means they have not got it yet

020 3080 6456
London, England The number if needed just called and asked about time scales
GLA

https://r.search.yahoo.com/_ylt=Awr.gZD21VtjVwIIOyd0g81Q;_ylu=Y29sbwNpcjIEcG9zAzgEdnRpZAMEc2VjA3Ny/RV=2/RE=1666991735/RO=10/RU=https%3a%2f%2fwww.gov.uk%2fguidance%2fclinical-trials-for-medicines-apply-for-authorisation-in-the-uk/RK=2/RS=8pHB9amXd10Y_ZqXa9TbNClL_04-
There is also a number which you can call and they give you the information about when a company will be notified Sareum will know by now just carnt understand why they are not informing the market why not unless it hasn’t been approved and needs more information

I’m sure years back they said 800m for each 1801/2 but was denied when I asked the question you just never know as the price might of gone up with the FDA approval and future possibilities of tyk2
GLA

If we got the same rise £10 a share would do me
GLA

Must be holding back the flood of buys rushing in until we get money in we are heading south again luckily consolidation has worked in our favour PH must be P@@sing them selves laughing at our BOD
GLA

Could be a good start for next year
CPF has been informed by Sierra Oncology that it intends to terminate the SRA737 licence agreement and return the rights for SRA737. Sareum will discuss with CPF the potential options for future development opportunities for SRA737 and evaluate its next steps accordingly. The SRA737 licence agreement has a 90-day notice period for termination, therefore the Company expects the rights to the programme to be returned to CPF during January 2023 and further updates will be made in due course, as and when appropriate.

Sierra had reported positive preliminary efficacy and safety data in two clinical trials evaluating it as a monotherapy and in combination with chemotherapy in 2019, and preclinical data have been reported that support the potential for SRA737 in combination against hard-to-treat cancers.

We continue to believe that, based on preclinical and early clinical data, SRA737 holds strong promise for the treatment of cancer, particularly in combination settings and are confident in the potential of this molecule
GLA

You would like to think this far up the line everything is sorted for a smooth transmission into clinical trials and all bases covered again until news released we can only surmise what is going to happen hopefully some news this week which will take the SP back up
GLA